

Nanexa granted patent in China

Nanexa AB (publ) today announced that the company has been granted a patent in China. This primary patent covers the manufacturing method, products that come out of it, and the use of PharmaShell®-coated drugs.

"This is an important milestone that we have worked hard and long for. As our primary patent has now been granted in the important markets of the USA, Japan and China, we have established broad patent protection connected to PharmaShell. I hope that we will be able to receive more patent approvals during the year," said David Westberg, CEO of Nanexa.

The patent application for the primary patent for the drug delivery system has also been filed in the European Patent Office, Canada, India and South Korea.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: david.westberg@nanexa.se

www.nanexa.com

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential for a number of medical substance types and indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with several pharma companies, among others AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

[Nanexa granted patent in China](#)